TaiGen Biopharmaceuticals Holdings Ltd 4157
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- TWD 14.50
- Day Range
- TWD 14.50–14.60
- 52-Week Range
- TWD 13.05–17.25
- Bid/Ask
- TWD 14.55 / TWD 14.60
- Market Cap
- TWD 10.44 Bil
- Volume/Avg
- 334,046 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- 347.85
- Price/Sales
- 72.36
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 77
- Website
- https://www.taigenbiotech.com/tw
Comparables
Valuation
|
Metric
|
4157
|
02171
|
02616
|
|---|---|---|---|
Price/Earnings (Normalized) | 347.85 | — | — |
Price/Book Value | 8.88 | 1.34 | — |
Price/Sales | 72.36 | 297.72 | 3.69 |
Price/Cash Flow | 176.54 | — | — |
Price/Earnings
4157
02171
02616
Financial Strength
|
Metric
|
4157
|
02171
|
02616
|
|---|---|---|---|
Quick Ratio | 19.37 | 9.12 | 1.42 |
Current Ratio | 20.34 | 9.47 | 1.56 |
Interest Coverage | 136.44 | −159.86 | −32.18 |
Quick Ratio
4157
02171
02616
Profitability
|
Metric
|
4157
|
02171
|
02616
|
|---|---|---|---|
Return on Assets (Normalized) | 4.77% | −29.55% | −20.01% |
Return on Equity (Normalized) | 5.29% | −39.55% | — |
Return on Invested Capital (Normalized) | 3.05% | −38.18% | −44.13% |
Return on Assets
4157
02171
02616
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Fjqznpkjnj | Lzjbh | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Blgrkwb | Hkchkwr | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pmqyhlxb | Qzlvstq | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mlkcqbzhv | Llxdk | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Fwtvrfgb | Dphz | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Qgznwkbq | Bgchj | $28.0 Bil | |||
| Moderna Inc
MRNA
| Kymhzxd | Jpdk | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Mcvghsty | Xqjt | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hshhtndq | Vjzfjlf | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Sxmqchfpb | Sxcdl | $12.6 Bil |
United States